Hoʻololi Peptide

Pepide Pegylation

Polyethylene glycol-peptide conjugates have a longer blood circulation time, higher solubility and lower immunogenicity.

What is Peptide Pegylation?

Peptide polyethylene glycolisation is the process of covalently attaching one or more polyethylene glycol (PEG) chains to a peptide molecule. Polyethylene glycolisation increases the molecular weight of the peptide, protects the peptide from hydrolysis by protein hydrolases, and ultimately improves the pharmacokinetics of the peptide.

Peptides play a vital role in the pharmaceutical industry and drug therapy development. Eia naʻe, the in vivo application of peptides is limited due to rapid degradation by proteolytic enzymes, poor solubility, antigenic reactions, and glomerular filtration in the kidney. Covalent linkage of polyethylene glycol (PEG) hoemi i ka immunogenicity, improves solubility and reduces renal clearance. The addition of monodisperse PEG chains is a key factor in the therapeutic development of PEGylated peptides. These safe and effective polyethylene glycolated peptides are essential for optimal therapeutic efficacy.

Peptide Pegylation scientists

Common PEG linkers and abbreviations

·Click Chemistry, which takes place between an azide group of the PEG reagent and an alkyne group of the peptide, or vice versa.
·Suzuki-Miyaura Coupling, which takes place between the iodophenyl group of the PEG reagent and an aryl boronic acid group of peptide, or vice versa..
·Sonogashira Coupling, which takes place between an iodophenyl group of the PEG reagent and an alkyne group of the peptide, or vice versa.

Abbrev.
Full PEG Chain Name

PEG

tetraethylene glycol

mini-PEG2

8-amino-3,6-dioxaoctanoic acid

mini-PEG3

amino-3,6,9-trioxaundecanoic acid

NH2-PEG2-acid

3-(2-(2-Aminoethoxy)ethoxy)-propanoic acid

PEG750

Poli(ethylene glycol) methyl ether (average Mn 750)

PEG1000

Poli(ethylene glycol) methyl ether (average Mn 1000)

PEG2000

Poli(ethylene glycol) methyl ether (average Mn 2000)

PEG5000

Poli(ethylene glycol) methyl ether (average Mn 5000)

Ester (OTBzl)

p-Nitroanilide

KLH (-COOH o ka pahu C)

tBu

Kuhikuhi Manawa

Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor

Imaging agents based on peptide probes have desirable pharmacokinetic properties provided that they have high affinities for their target in vivo. An approach to improve a peptide ligand’s affinity for its target is to make this interaction covalent and irreversible. For this purpose, we evaluated a 64Cu-labeled affinity peptide tag, 64Cu-L19K-(5-fluoro-2,4-dinitrobenzene) (64Cu-L19K-FDNB), which binds covalently and irreversibly to vascular endothelial growth factor (VEGF) as a PET imaging agent. We compared the in vivo properties of 64Cu-L19K-FDNB in VEGF-expressing tumor xenografts with its noncovalent binding analogs, 64Cu-L19K-(2,4-dinitrophenyl) (64Cu-L19K-DNP) and 64Cu-L19K. Nā ʻano hana: The L19K peptide (GGNECDIARMWEWECFERK-CONH2) was constructed with 1,4,7-triazacyclononane-1,4,7-triacetic acid at the N terminus for radiolabeling with 64Cu with a polyethylene glycol spacer between peptide and chelate. 1,5-difluoro-2,4-dinitrobenzene was conjugated at the C-terminal lysine for cross-linking to VEGF, resulting in L19K-FDNB. 64Cu-L19K-FDNB was assayed for covalent binding to VEGF in vitro. As a control, L19K was conjugated to 1-fluoro-2,4-dinitrobenzene, resulting in L19K-DNP. PET imaging and biodistribution studies of 64Cu-L19K-FDNB, 64Cu-L19K-DNP, and the native 64Cu-L19K were compared in HCT-116 xenografts. Blocking studies of 64Cu-L19K-FDNB was performed with a coinjection of excess unlabeled L19K-FDNB. Nā hualoaʻa: In vitro binding studies confirmed the covalent and irreversible binding of 64Cu-L19K-FDNB to VEGF, whereas 64Cu-L19K-DNP and 64Cu-L19K did not bind covalently. PET imaging showed higher tumor uptake with 64Cu-L19K-FDNB than with 64Cu-L19K-DNP and 64Cu-L19K, with mean standardized uptake values of 0.62 ± 0.05, 0.18 ± 0.06, a 0.34 ± 0.14, pakahi, ma 24 h after injection (P < 0.05), a 0.53 ± 0.05, 0.32 ± 0.14, a 0.30 ± 0.09, pakahi, ma 48 h after injection (P < 0.05). Blocking studies with 64Cu-L19K-FDNB in the presence of excess unlabeled peptide showed a 53% reduction in tumor uptake at 48 h after injection. Ka hopena: In this proof-of-concept study, the use of a covalent binding peptide ligand against VEGF improves tracer accumulation at the tumor site in vivo, compared with its noncovalent binding peptide analogs. This technique is a promising tool to enhance the potency of peptide probes as imaging agents.

Nā lawelawe hoʻololi peptide pili

peptide glycosylation

peptide glycosylation

ʻO ka peptide glycosylation kahi hoʻololi covalent i hiki ke hoʻomaikaʻi i nā waiwai physicochemical o nā peptides.

Heluhelu hou aku

peptide Phosphorylation

peptide Phosphorylation

Hiki mai paha ka Phosphoralation ma Serine (S, E lilo), Threonine (Ua ʻōlelo ʻo T, ʻO Thr) a me Tyrosine (Y, ʻO Tyr) nā kaulahao ʻaoʻao e ka hoʻokumu ʻana i ka paʻa phosphoester

Heluhelu hou aku

Nā Peptides Stapled

Nā Peptides Stapled

ʻO ka hoʻolauna ʻana i ʻelua mau waikawa amino kūlohelohe i loaʻa ka α-methyl, Nā pūʻulu α-alkenyl i ka wā paʻa-phase synthesis o nā kaulahao peptide.

Heluhelu hou aku

Cyclic Peptide

Cyclic Peptide

Hoʻonui ka cyclization i ka conformational stability o nā peptides (pili i kā lākou mau analogues linear) a he hoʻolālā maʻamau i ka hoʻomohala ʻana i ka peptide.

Heluhelu hou aku

hoʻololi peptide

ʻIke nui i ka hoʻololi peptide, hāʻawi i nā ala kūpono he nui no ka noiʻi peptide.

Home Huli Whatsapp Nā lawelawe Huahana